Nicotinamide Riboside Fails NOPARK Despite Raising Blood NAD

A JAMA release dated 2026-10-08 reported results from NOPARK, a phase 3 trial of nicotinamide riboside (NR) conducted at 11 centers in Norway.

Placebo Came Ahead

The JAMA release said the results do not support NR as a disease-modifying treatment for Parkinson's disease. According to Medscape, total MDS-UPDRS symptom scores rose by 2.45 points with NR and fell by 0.27 points with placebo at week 52. The adjusted difference was 2.72 points in favor of placebo (P=.02). For healthy-aging research, the central lesson is the separation between a supplement's measurable biological activity and its effect on patient outcomes: NR increased blood NAD without improving the clinical result.

A Human Test

Evidence level: Humans, in a randomized clinical trial.

According to Medscape, NOPARK enrolled 410 adults aged 35 or older with early Parkinson's disease. Participants had received their diagnosis within the previous two years. They were assigned to NR 500 mg twice daily or matching placebo for 52 weeks. The trial was randomized and double-blind.

These design features make the assigned groups the central comparison. The question was not simply whether someone taking NR experienced a change over time. It was whether the NR group had better clinical outcomes than the placebo group over the same study period. That distinction is essential when evaluating a proposed treatment rather than collecting impressions about supplement use.

Lead investigator Charalampos Tzoulis described NOPARK to Medscape as “the first study large and long enough to test efficacy reliably.” That was his assessment of the trial's role in evaluating NR. It helps explain why this result deserves attention alongside the biological rationale that motivated interest in the compound.

Medscape also reported worse nonmotor symptom results with NR. The adjusted difference on the Non-Motor Symptoms Scale was 4.22 points in favor of placebo (P=.009). The groups did not differ significantly on individual MDS-UPDRS scores or cognition. Nor did they differ significantly on Hoehn and Yahr disease stage.

Taken together, these findings put clinical outcomes at the center of the story. The trial's value lies in testing a proposed benefit against a comparison group rather than assuming that biological activity would deliver that benefit.

The NAD Response

NR did produce a measurable biological response. Medscape reported a between-group difference in blood NAD of 30.00 μM in favor of NR (P<.001). The intervention therefore changed the reported blood marker even though the clinical comparison did not favor the supplement.

Tzoulis summarized that contrast directly: “NR produced a clear systemic metabolic response, but this did not translate into clinical benefit.” His statement identifies the central disconnect in NOPARK. The blood measurement and the patient outcome answered different questions.

A biomarker asks whether a biological signal changed. A clinical endpoint asks whether the outcome being sought actually improved. In this trial, a positive answer to the first question did not supply a positive answer to the second. Reporting both results is more informative than treating either one as the complete story.

This distinction is especially useful when interpreting claims built around NAD. A claim that NR increases blood NAD describes a measured metabolic response. A claim that NR slows Parkinson's progression requires evidence from clinical outcomes. NOPARK supplied evidence for the former without supporting the latter.

For readers assessing longevity research, the useful habit is to identify which question a measurement answers before deciding what it means. AgeAmaze's discussion of intermediate biological responses in longevity trials provides related context for that distinction. The editorial priority is not to dismiss biomarkers but to keep their role separate from the benefit an intervention is intended to deliver.

Interpreting The Limits

Several boundaries determine how far the NOPARK result should travel:

• The population was disease-specific. NOPARK studied people with early Parkinson's disease. It did not measure lifespan or healthy-aging outcomes in the general population. The result therefore cannot establish either broad aging benefits or their absence in healthy adults. Claims about those outcomes need evidence collected in the relevant population rather than a conclusion transferred from this trial.
• The regimen was defined. The findings apply to the tested dose and duration. Other doses or treatment periods were not the comparison NOPARK was designed to resolve. That boundary does not turn an untested alternative into a promising treatment; it identifies a separate research question that would need its own clinical evidence.
• Statistical significance was not the same as individual clinical importance. Medscape reported that the primary-score difference was below the threshold generally considered clinically meaningful for an individual patient. The result still weighs against the proposed benefit. It should not be retold as proof that every participant experienced a noticeable worsening because of NR.
• Adverse-event rates do not establish causation or universal safety. Medscape reported adverse events in 54.6% of NR recipients and 53.7% of placebo recipients. Those overall rates alone do not show that NR caused harm. They also do not establish safety for every person or use. The negative efficacy finding and the adverse-event comparison are distinct parts of the evidence.
• One precursor is not the whole NAD field. Medscape reported that Tzoulis cautioned against treating NOPARK as evidence that NAD biology is irrelevant to Parkinson's disease. He also expressed skepticism that simply substituting another NAD precursor would fundamentally change the result. That is expert commentary rather than a comparison tested by NOPARK. Thinking about aging pathways as a research map helps keep a single intervention from standing in for an entire field.

Healthy-Aging Plans

A separate research announcement addresses the healthy-aging question more directly. In September 2026, Niagen Bioscience announced a start-up agreement with Mass General Brigham investigators to begin planning a proposed randomized, placebo-controlled NR trial. The intended population was apparently healthy adults aged 50 and older.

According to the company's announcement, the proposed study might assess clinical and functional outcomes alongside wellness measures and biomarkers. Its sample size and dose remained subject to planning and final agreements. The same was true of its duration and endpoints. The announcement was a research plan rather than evidence that enrollment had begun or that NR improved healthy aging.

The connection to NOPARK is methodological rather than a prediction of success or failure. A study intended to evaluate healthy-aging benefits needs to define those benefits clearly enough to test them. Otherwise, a change in a blood measurement can remain disconnected from the outcome that made the intervention interesting in the first place.

Reading The Claims

The practical reading of NOPARK is straightforward: NR should not be presented as an established treatment for slowing early Parkinson's disease. A description of its blood NAD response should remain a description of that response. The clinical claim has to be judged against the clinical comparison rather than rescued by a favorable laboratory measurement.

For any supplement claim, identify the promised outcome first. Then check whether the supporting study measured that outcome in a relevant population. This keeps a statement about metabolic activity from quietly becoming a statement about neurological protection or longer healthy life. Personal decisions about Parkinson's treatment or supplement use belong in a discussion with a qualified clinician.

The Next Test

The next useful step is a fully specified randomized trial in the population of interest that tests meaningful clinical or functional outcomes alongside NAD measurements rather than treating the biomarker response as sufficient validation.

How AgeAmaze helps

Nicotinamide riboside illustrates the distance between metabolic activity and therapeutic value, a distinction AgeAmaze addresses through research-led explanations rather than supplement promises. For adults weighing overstated longevity claims, the publication clarifies mechanisms and evidence strength to help separate established findings from promising ideas and speculation.

Read the research

Sources

1. media.jamanetwork.com · media-releases · 10Nicotinamide Riboside for Patients With Early-Stage Parkinson...
2. News Details
3. Healthy Aging Supplement Fails in Large PD Trial